This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
Research Site
Glendale, California, United States
Research Site
Baltimore, Maryland, United States
Safety and tolerability; Adverse events (AEs), vital signs, physical examinations, ECGs and clinical laboratory assessments
Time frame: During the study
Pharmacokinetic - Pharmacokinetic parameters for AZD6765 in plasma and urine
Time frame: During residential period
Genetics; Collect blood samples for optional exploratory genetic studies focusing on identification of genes that influence the disposition, efficacy, safety and tolerability of AZD6765.
Time frame: During the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.